• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights of People with ALS/MND and Caregivers
    • Research
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
    • Drugs in Development
      • AB Science – Masitinib
      • Amylyx – AMX0035
      • Biogen – Tofersen
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Orphazyme – Arimoclomol
      • T Regulatory Cell Therapies
    • Approved Drugs
      • Radicava/Edaravone
      • Neudexta
      • Riluzole/Tiglutik
  • Support for Health Professionals
    • How to Break the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Webinars
    • Alliance Meeting
    • Allied Professionals Forum
    • ALS/MND Connect
    • Global Day
    • March of Faces
    • International Symposium on ALS/MND
  • About
    • Who We Are
    • Board of Directors
    • Committees/Advisory Councils
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Governance Committee
      • Budget and Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Student Award Nomination
      • Forbes Norris Award Nomination
      • Humanitarian Award Nomination
      • Allied Health Professional Award Nomination
  • Members
    • Member Registration
    • Forgot Password

ALS Netherlands

Netherlands
Date founded: 1 January 2005
Region covered:

The Netherlands


Address:

Koninginnegracht 7
2514 AA The Hague
The Netherlands


ALS Netherlands Activities

  • Granting (financial) support to and promotion of research to causes of ALS and research to cure or prevent the disease
  • Increase of available knowledge in this area by stimulating scientific researching a broad sense, particularly aimed at the cause and the prevention of ALS, but also on treatment and rehabilitation of patients.
  • Making available information on the causes and treatment of ALS.
  • Promotion training of experts both in the medical and non-medical disciplines and promotion of additional studying to doctors and others involved in care of patients
  • Initiate and maintain contacts with institutions, organisations and agencies which can contribute to the fight of ALS/MND.
  • Initiate and maintain contacts, and cooperate with pharmaceutical companies in areas where they contribute to the fight of ALS/MND
  • Doing advocacy for people with ALS in the broadest sense of the word.
  • Maintain a knowledge centre on ALS.
  • Stimulate awareness of ALS.
  • Initiate, manage, develop funds to support all aforesaid objectives
  • All other activities that contribute to the goals and objectives goals and objectives.

The foundation tries to reach these goals and objectives by all legitimate resources, such as,

  • Acquiring and invest reinvesting resources, and securities and its revenues.
  • Acquiring donations, legacy and heritages.
  • Fund raising in a broad sense of the word.
  • Granting benefits or supply loans to persons or institutions operative or doing research in the field of ALS/MND.

ALS Netherlands Branches/Chapters

4

Contacts

  • Gorrit-Jan Blonk, Director
  • Marjan Sterenborg, Marketing & Communication Manager

Phone:

+31 886660333

Email:

info@als.nl

Website:

www.als.nl

Facebook:

www.facebook.com/ALSnederland

Twitter:

twitter.com/ALSnederland

YouTube:

www.youtube.com/user/StichtingALS

Primary Sidebar

Back to all

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2023 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login